Cardiology

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The expanded approval provides young pediatric patients with a proven, effective treatment to significantly reduce dangerously high LDL-C levels.

A national poll finds few parents have their teens evaluated for heart disease, while gaps in training highlight ongoing challenges in responding to sudden cardiac arrest.

A study found high rates of neurodevelopmental diagnoses and service use among children with congenital heart disease following infant heart surgery.

A study found that more than two-thirds of adolescents with congenital heart disease experience at least one cardiac or noncardiac comorbidity.

Phase 3 SCOUT-HCM results showed mavacamten significantly reduced LVOT gradient vs placebo in adolescents with obstructive HCM.

Abbott received FDA clearance for a new delivery system designed to simplify PDA closure in premature infants weighing as little as 2 lb.

A health system–wide lipid screening pathway significantly increased pediatric screening rates across a large primary care network.

New 2025 AHA CPR guidelines update choking response, opioid overdose care, and pediatric training to improve survival outcomes.

Updated 2025 CPR guidelines from the AAP and AHA include revisions to pediatric and neonatal resuscitation, reflecting new evidence and a unified chain of survival.

The approval expands on the previous indication of children 5 years and older with HoFH, approved in 2023.

Try to diagnose this patient with a history of receptive-expressive speech disorder and anxiety.

Try to diagnose this patient with a history of receptive-expressive speech disorder and anxiety.

Solid Biosciences is planning a phase 1b clinical trial of SGT-501 to treat the catecholaminergic polymorphic ventricular tachycardia heart condition.

Childhood cardiovascular health is crucial for lifelong benefits, enhancing cognitive, metabolic, and mental well-being while reducing disease risks.

Prenatal PFAS exposure was linked to higher adolescent blood pressure according to a recent study.

Currently, omaveloxolone (Skyclarys) is approved to treat adults and adolescents aged 16 years and older impacted by FA.

This FDA decision will help to improve clarity and diagnostic accuracy of echocardiograms in pediatric patients, according to GE HealthCare.

In this article, we recap our top stories, expert interviews, and Q+A discussions from the 2025 Pediatric Academic Societies meeting.

Stealth BioTherapeutics' CEO stated, "We hope to gain more information on the revised action date in the coming days."

Do you know the details from the American Academy of Pediatrics' 2024 CCHD updated screening recommendations?

Submission is based on 3 clinical trials, including data from the ApproaCH Trial among children with achondroplasia.

Pediatric cancer survivors can be vulnerable to cardiovascular disease in the short- or long-term with increased recognition of cardiotoxic cancer treatments, as 5-year survival rates for children are greater than 85%.

An overview of commercially available infant cardiorespiratory monitors and pulse oximeters in the home.

Find out how you did on the quiz.